Clinical trials
Recruiting Phase 2 Burkitt Lymphoma trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
23 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 3 |
| 2025 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 23 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 4 |
| M.D. Anderson Cancer Center | 2 |
| Masonic Cancer Center, University of Minnesota | 2 |
| The First Affiliated Hospital of Soochow University | 2 |
| Beijing Tongren Hospital | 1 |
| Beijing Yongtai Ruike Biotechnology Company Ltd | 1 |
| City of Hope Medical Center | 1 |
| Etan Orgel | 1 |
| Fred Hutchinson Cancer Center | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Burkitt Lymphoma | 23 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 |
| Lymphoma, Follicular | 5 |
| Lymphoma, Large B-Cell, Diffuse | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
| Lymphoma, B-Cell, Marginal Zone | 4 |
| Leukemia, Biphenotypic, Acute | 3 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 |
| Leukemia, Myeloid, Acute | 3 |
| Leukemia, Prolymphocytic | 3 |
Trials
Showing 1 to 23 of 23. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.